Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Illumina, Inc. stock logo
ILMN
Illumina
$198.00
-4.4%
$249.02
$112.65
▼
$309.35
$29.94B1.462.18 million shs1.52 million shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Illumina, Inc. stock logo
ILMN
Illumina
0.00%-2.87%-21.15%+7.19%+71.55%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Illumina, Inc. stock logo
ILMN
Illumina
$198.00
-4.4%
$249.02
$112.65
▼
$309.35
$29.94B1.462.18 million shs1.52 million shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Illumina, Inc. stock logo
ILMN
Illumina
0.00%-2.87%-21.15%+7.19%+71.55%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Illumina, Inc. stock logo
ILMN
Illumina
2.37
Hold$244.2423.35% Upside

Current Analyst Ratings Breakdown

Latest ILMN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/2/2026
Illumina, Inc. stock logo
ILMN
Illumina
UpgradeHold (C) ➝ Buy (B-)
11/2/2026
Illumina, Inc. stock logo
ILMN
Illumina
Boost Price TargetSell$113.00 ➝ $210.00
10/30/2026
Illumina, Inc. stock logo
ILMN
Illumina
Reiterated RatingUnderperform
10/30/2026
Illumina, Inc. stock logo
ILMN
Illumina
Lower Price TargetOverweight$320.00 ➝ $300.00
10/23/2026
Illumina, Inc. stock logo
ILMN
Illumina
DowngradeOverweight ➝ Equal Weight$275.00
10/23/2026
Illumina, Inc. stock logo
ILMN
Illumina
DowngradeOverweight ➝ Equal Weight$275.00
10/19/2026
Illumina, Inc. stock logo
ILMN
Illumina
Boost Price TargetHold$205.00 ➝ $300.00
10/13/2026
Illumina, Inc. stock logo
ILMN
Illumina
Boost Price TargetHold$210.00 ➝ $270.00
10/7/2026
Illumina, Inc. stock logo
ILMN
Illumina
Boost Price TargetUnderweight$160.00 ➝ $200.00
10/5/2026
Illumina, Inc. stock logo
ILMN
Illumina
Boost Price TargetOutperform$230.00 ➝ $310.00
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Illumina, Inc. stock logo
ILMN
Illumina
$4.34B6.89$6.42 per share30.83$17.82 per share11.11
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Illumina, Inc. stock logo
ILMN
Illumina
$850M$5.8134.0831.882.8119.72%28.38%12.11%2/4/2027 (Estimated)

Latest ILMN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/29/2026Q3 2026
Illumina, Inc. stock logo
ILMN
Illumina
$1.36$1.62+$0.26$1.43$1.15 billion$1.17 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Illumina, Inc. stock logo
ILMN
Illumina
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Illumina, Inc. stock logo
ILMN
Illumina
0.57
2.63
2.05

Institutional Ownership

CompanyInstitutional Ownership
Illumina, Inc. stock logo
ILMN
Illumina
89.42%

Insider Ownership

CompanyInsider Ownership
Illumina, Inc. stock logo
ILMN
Illumina
2.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Illumina, Inc. stock logo
ILMN
Illumina
8,650151.20 million146.82 millionOptionable

Recent News About These Companies

Illumina (NASDAQ:ILMN) Stock: Insider Scott Ericksen Sells 267 Shares
Is Illumina Stock Worth The Wait?
How Investors May Respond To Illumina (ILMN) Earnings Beat
Missed Illumina's 76% Run? Here Is What Holders Saw
12,886 Illumina, Inc. $ILMN Shares Sold by M&G PLC
Illumina, Inc. $ILMN Stock: Candriam S.C.A. Reduces Stake

New MarketBeat Followers Over Time

Media Sentiment Over Time

Illumina stock logo

Illumina NASDAQ:ILMN

$198.00 -9.01 (-4.35%)
Closing price 04:00 PM Eastern
Extended Trading
$198.73 +0.73 (+0.37%)
As of 05:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.